Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | GRM8 | O00222 | 4/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.53 |
| ▸ | GRM6 | O15303 | 3/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666885 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL16293830 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL3310878 | 1.00 | KMO (0.55) | KMOGRM8GRM4GRM6ACP3 | |
| Hydrochloric Acid SCHEMBL3812830 | 0.98 | KMO (0.53) | KMOGRM8GRM4GRM6ACP3 | |
| Hydrochloric Acid SCHEMBL3812833 | 0.98 | KMO (0.53) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL9263216 | 0.88 | TSHR (0.51) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL666558 | 0.85 | GRM8 (0.54) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL16933041 | 0.84 | ACP3 (0.54) | KMOGRM8GRM4GRM6ACP3 | |
| SCHEMBL665345 | 0.83 | MEN1 (0.51) | KMOGRM8GRM4GRM6SMN1; SMN2 | |
| SCHEMBL8297473 | 0.83 | MEN1 (0.51) | KMOGRM8GRM4GRM6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1971582-B1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-101389613-B | Macrocyclic factor viia inhibitors useful as anticoagulants | BRISTOL MYERS SQUIBB CO | 2011-10-12 | — | — | CN | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| CN-101389613-A | Macrocyclic factor viia inhibitors useful as anticoagulants | BRISTOL MYERS SQUIBB CO (US) | 2009-03-18 | — | — | CN | disclosed |
| EP-1971582-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1146541-C | Beta-alanine derivatives | Ĭ��ר���ɷ�����˾ | 2004-04-21 | — | — | CN | disclosed |
| US-6576637-B1 | Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, | MERCK PATENT GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
| CN-1340046-A | Beta-alanine derivatives | MERCK PATENT GMBH (DE) | 2002-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | KMO 2667/4885GRM8 4078/4885GRM4 4601/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | KMO 2667/4885GRM8 4078/4885GRM4 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.